Add KDNY to watchlist(s)

You Should Create a Watchlist In The First Place.

Profile

Company Name

Chinook Therapeutics, Inc.

Symbol

KDNY

Currency

USD

Exchange

Nasdaq

Head Quarter

United States, Seattle

Sector

Healthcare

Industry

Biotechnology

Website

https://www.chinooktx.com

ISIN

US00739L1017

CIK

1435049

CUSIP

16961L106

UEI

LEI

Business Description

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases.